68 related articles for article (PubMed ID: 8943405)
1. Humanization of an anti-lymphocyte function-associated antigen (LFA)-1 monoclonal antibody and reengineering of the humanized antibody for binding to rhesus LFA-1.
Werther WA; Gonzalez TN; O'Connor SJ; McCabe S; Chan B; Hotaling T; Champe M; Fox JA; Jardieu PM; Berman PW; Presta LG
J Immunol; 1996 Dec; 157(11):4986-95. PubMed ID: 8943405
[TBL] [Abstract][Full Text] [Related]
2. Anti-(human LFA-1) monoclonal antibodies bind P815 murine tumour cells.
Palisson MJ; Altemeyer A; Moosbrugger I; Warter S; Hauptmann G; Bischoff P
Cancer Immunol Immunother; 1992; 34(6):407-13. PubMed ID: 1373342
[TBL] [Abstract][Full Text] [Related]
3. A universal in silico V(D)J recombination strategy for developing humanized monoclonal antibodies.
Hsieh YC; Liao JM; Chuang KH; Ho KW; Hong ST; Liu HJ; Huang BC; Chen IJ; Liu YL; Wang JY; Tsai HL; Su YC; Wang YT; Cheng TL
J Nanobiotechnology; 2022 Jan; 20(1):58. PubMed ID: 35101043
[TBL] [Abstract][Full Text] [Related]
4. Lessons learned from merging wet lab experiments with molecular simulation to improve mAb humanization.
Schwaigerlehner L; Pechlaner M; Mayrhofer P; Oostenbrink C; Kunert R
Protein Eng Des Sel; 2018 Jul; 31(7-8):257-265. PubMed ID: 29757445
[TBL] [Abstract][Full Text] [Related]
5. IgG light chain-independent secretion of heavy chain dimers: consequence for therapeutic antibody production and design.
Stoyle CL; Stephens PE; Humphreys DP; Heywood S; Cain K; Bulleid NJ
Biochem J; 2017 Sep; 474(18):3179-3188. PubMed ID: 28784690
[TBL] [Abstract][Full Text] [Related]
6. Overcoming a species-specificity barrier in development of an inhibitory antibody targeting a modulator of tumor stroma.
Grossman I; Ilani T; Fleishman SJ; Fass D
Protein Eng Des Sel; 2016 Apr; 29(4):135-47. PubMed ID: 26819240
[TBL] [Abstract][Full Text] [Related]
7. Targeted Delivery of LXR Agonist Using a Site-Specific Antibody-Drug Conjugate.
Lim RK; Yu S; Cheng B; Li S; Kim NJ; Cao Y; Chi V; Kim JY; Chatterjee AK; Schultz PG; Tremblay MS; Kazane SA
Bioconjug Chem; 2015 Nov; 26(11):2216-22. PubMed ID: 25945727
[TBL] [Abstract][Full Text] [Related]
8. Biologics in dermatology: an integrated review.
Sehgal VN; Pandhi D; Khurana A
Indian J Dermatol; 2014 Sep; 59(5):425-41. PubMed ID: 25284845
[TBL] [Abstract][Full Text] [Related]
9. Increased polyamine intake inhibits age-associated alteration in global DNA methylation and 1,2-dimethylhydrazine-induced tumorigenesis.
Soda K; Kano Y; Chiba F; Koizumi K; Miyaki Y
PLoS One; 2013; 8(5):e64357. PubMed ID: 23696883
[TBL] [Abstract][Full Text] [Related]
10. Leukocyte traffic blockade as a therapeutic strategy in inflammatory bowel disease.
Bamias G; Clark DJ; Rivera-Nieves J
Curr Drug Targets; 2013 Nov; 14(12):1490-500. PubMed ID: 23621509
[TBL] [Abstract][Full Text] [Related]
11. Suppression of LFA-1 expression by spermine is associated with enhanced methylation of ITGAL, the LFA-1 promoter area.
Kano Y; Soda K; Konishi F
PLoS One; 2013; 8(2):e56056. PubMed ID: 23418509
[TBL] [Abstract][Full Text] [Related]
12. On the potential involvement of CD11d in co-stimulating the production of interferon-γ by natural killer cells upon interaction with neutrophils via intercellular adhesion molecule-3.
Costantini C; Micheletti A; Calzetti F; Perbellini O; Tamassia N; Albanesi C; Vermi W; Cassatella MA
Haematologica; 2011 Oct; 96(10):1543-7. PubMed ID: 21712539
[TBL] [Abstract][Full Text] [Related]
13. Biologics in the management of psoriasis.
Bahner JD; Cao LY; Korman NJ
Clin Cosmet Investig Dermatol; 2009 Jul; 2():111-28. PubMed ID: 21436974
[TBL] [Abstract][Full Text] [Related]
14. Engineering the variable region of therapeutic IgG antibodies.
Igawa T; Tsunoda H; Kuramochi T; Sampei Z; Ishii S; Hattori K
MAbs; 2011; 3(3):243-52. PubMed ID: 21406966
[TBL] [Abstract][Full Text] [Related]
15. Efalizumab, a human monoclonal anti-CD11a antibody, in the treatment of moderate to severe Crohn's Disease: an open-label pilot study.
James DG; Seo DH; Chen J; Vemulapalli C; Stone CD
Dig Dis Sci; 2011 Jun; 56(6):1806-10. PubMed ID: 21170755
[TBL] [Abstract][Full Text] [Related]
16. Pathogenic mechanisms shared between psoriasis and cardiovascular disease.
Ghazizadeh R; Shimizu H; Tosa M; Ghazizadeh M
Int J Med Sci; 2010 Aug; 7(5):284-9. PubMed ID: 20827428
[TBL] [Abstract][Full Text] [Related]
17. Potential aggregation prone regions in biotherapeutics: A survey of commercial monoclonal antibodies.
Wang X; Das TK; Singh SK; Kumar S
MAbs; 2009; 1(3):254-67. PubMed ID: 20065649
[TBL] [Abstract][Full Text] [Related]
18. Efalizumab in the treatment of psoriasis.
Boehncke WH
Biologics; 2007 Sep; 1(3):301-9. PubMed ID: 19707339
[TBL] [Abstract][Full Text] [Related]
19. Ustekinumab: a new option in psoriasis therapy.
Chien AL; Elder JT; Ellis CN
Drugs; 2009 Jun; 69(9):1141-52. PubMed ID: 19537833
[TBL] [Abstract][Full Text] [Related]
20. Improving the species cross-reactivity of an antibody using computational design.
Farady CJ; Sellers BD; Jacobson MP; Craik CS
Bioorg Med Chem Lett; 2009 Jul; 19(14):3744-7. PubMed ID: 19477127
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
